BioMotiv Competitors, Revenue, Alternatives and Pricing
Overview
Estimated Revenue & Financials
- BioMotiv's estimated annual revenue is currently $8.4M per year.
- BioMotiv received $63.0M in venture funding in August 2016.
- BioMotiv's estimated revenue per employee is $155,000
- BioMotiv's total funding is $435.1M.
Employee Data
- BioMotiv has 54 Employees.
- BioMotiv grew their employee count by 17% last year.
- BioMotiv currently has 1 job openings.
BioMotiv Competitors
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Online Review | Pricing |
|---|---|---|---|---|---|---|
| Advertise Here | ||||||
#1 | N/A | 81 | N/A | N/A | - | N/A |
#2 | $15.2M | 98 | 9% | N/A | - | N/A |
#3 | $8.4M | 54 | 29% | N/A | - | N/A |
#4 | $8.4M | 54 | 17% | N/A | - | N/A |
#5 | $10.1M | 65 | 25% | N/A | - | N/A |
#6 | N/A | 272 | N/A | N/A | - | N/A |
#7 | $8.1M | 52 | 225% | N/A | - | N/A |
What Is BioMotiv?
BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development, a $340 million US and UK initiative for advancing medicine centered at University Hospitals in Cleveland. The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations. The company leverages an experienced team and advisory board to select, fund, and actively manage and advance a portfolio of programs.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power54
Number of Employees
$8.4M
Revenue (est)
1
Current Jobs
17%
Employee Growth %
$435.1M
Total Funding
N/A
Valuation
N/A
Accelerator
B2B
Type
BioMotiv News
Bristol-Myers Squibb has allied with biotech accelerator BioMotiv. The deal sets Bristol-Myers up to found and fund biotechs with BioMotiv ...
CLEVELAND & NEW YORK--(BUSINESS WIRE)--BioMotiv, a mission-driven drug development accelerator that advances breakthrough ...
Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis ...
BioMotiv Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2012-09-06 | $21.0M | Undisclosed | University Hospitals, Harrington Family | Article |
| 2013-08-06 | $46.0M | Undisclosed | Nationwide Mutual Insurance Co | Article |
| 2014-08-15 | $51.0M | Undisclosed | Article | |
| 2014-09-29 | $25.0M | Undisclosed | Takeda Pharmaceutical Company Limited | Article |
| 2016-04-15 | $10.0M | Undisclosed | Charles River Laboratories International Inc | Article |
| 2016-08-09 | $63.0M | Undisclosed | Article |